EAP now covering Actemra for JIA

Click here for new EAP crtieria for polyarticular JIA, now including Actemra […]

Read More…


Methotrexate injectable availability

Methotrexate 50mg/2mL with Preservative Vials – Sandoz vs Mayne Brand The Sandoz product, DIN#02398427, is now the only product reimbursed by the Ontario Drug Benefit program at a cost of $8.92. Click here […]

Read More…


ORA launches new website Rheumcareers

The ORA has launched Rheumcareers, a new website to increase rheumatology visibility to medical students/PGY1 and 2 as well as serving as a tool to help rheumatology residents find employment once their training […]

Read More…


New Diclofenac dosages and warnings from Health Canada

Diclofenac: New maximum dose is 100 mg/day.  Click here to see more information […]

Read More…


Summer Newsletter

Click here for the Summer 2014 ORA Newsletter. The newsletter includes an update from the new ORA President, Dr. Arthur Karasik. It also includes information regarding the EMR application deadline. […]

Read More…


ORA and OPA Collaboration – Enhancing Patient Care through the Use of MedsCheck

The ORA Models of Care Committee and the Ontario Pharmacists Association have partnered together to strengthen inter-professional communication and collaboration to enhance and optimize the quality of care for their patients. ORA/OPA Communication […]

Read More…


EMR Articles

Please find the following 3 interesting articles regarding EMR: Five Issues That Prevent From Using Your EMR Effectively Doctor’s 10 Biggest Mistakes When Using EHR’s Doctor’s Are Talking: EHRs Destroy the Patient Encounter […]

Read More…


Forteo now covered by EAP to treat AVN of jaw and Bisphosphonate-related atypical femoral fractures

Forteo now covered by EAP to treat AVN of jaw and Bisphosphonate-related atypical femoral fractures. Criteria for this can be found here […]

Read More…


Drug Shortage Update

As many of you may be aware (especially our pediatric colleagues), there has been a recent unavailability of Naprosyn in liquid Suspension form. This product has been ‘owned’ by Roche Canada, for the […]

Read More…


Models of Care – May 2014

 The Models of Care committee has identified several key initiatives to help to support the Ontario Framework. Click here for the communication piece. […]

Read More…